AAP
IMNM icon

Arax Advisory Partners’s Immunome IMNM Stock Holding History

Arax Advisory Partners’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.42K Buy
+114
New +$2.44K ﹤0.01% 4778
2026
Q1 		– Sell
-19
Closed -$408 – 4060
2025
Q4 		$408 Sell
19
-101
-84% -$1.77K ﹤0.01% 3636
2025
Q3 		$1.41K Buy
+120
New +$1.19K ﹤0.01% 3182
2025
Q2 		– Sell
-69
Closed -$465 – 3126
2025
Q1 		$465 Buy
+69
New +$662 ﹤0.01% 2543

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Arax Advisory Partners's IMNM Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Immunome (IMNM) in Q2 2026: 114 shares worth $2.42K. The stake represents ﹤0.01% of the portfolio and ranks #4778 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in IMNM as recently as Q4 2025.

Arax Advisory Partners first reported a position in IMNM in Q1 2025 and has held it in 4 quarters since. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Arax Advisory Partners held 114 shares of Immunome worth $2.42K as of Q2 2026.
  • Immunome was a new Arax Advisory Partners position in Q2 2026.
  • Immunome made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4778 holding.
  • Arax Advisory Partners first reported a position in Immunome in Q1 2025 and has held it in 4 quarters since.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.